Goodwin Procter is pleased to announce that its Life Sciences Practice won four awards at the 2013 LMG Life Sciences Awards in New York City on September 25. The inaugural event recognized the life sciences industry’s leading legal advisors and most transformative deals and cases from the last year.
Goodwin was awarded Venture Capital Firm of the Year and was also recognized for its work on behalf of clients in three separate Impact Cases and Deals categories, including: M&A Impact Deal of the Year (representing Avila Therapeutics in its sale to Celgene); Venture Capital Impact Deal of the Year (representing Moderna Therapeutics in its option deal with AstraZeneca); and Hatch-Waxman Impact Case of the Year (successfully representing Teva Pharmaceuticals in Eli Lilly & Co et al v Teva Parenteral Medicines Inc et al).
In total, Goodwin was shortlisted in 11 categories, including: Venture Capital Firm of the Year; IP Firm of the Year; Patent Strategy and Management Team of the Year; and Hatch-Waxman (Generic) Litigation Team of the Year. Two of our partners were recognized in Attorney of the Year categories: Mitchell Bloom (Corporate Advisory; Finance and Transactional; M&A) and Kingsley Taft (Corporate Advisory; Finance and Transactional; Venture Capital). The firm won all three of the Deals and Cases categories for which it received nominations: M&A Impact Deal of the Year; Venture Capital Impact Deal of the Year; and Hatch-Waxman Impact Case of the Year.
In addition to recognition at the awards gala, LMG Life Sciences recently recognized a variety of our attorneys and practices in its second annual industry guide. Goodwin is acknowledged as one of the industry’s few Life Cycle Firms who have "across-the-board" capabilities in Finance & Transactional, Intellectual Property, Regulatory, and Non-IP Litigation & Enforcement practices. Fifteen of our partners are recognized as “Life Sciences Stars.”
For more information on Goodwin’s Life Sciences Practice, click here.